Figure 7
Clinical validation of miR-200c and USP25. (A,E) Real-time PCR analysis to quantify the levels of miR-200c, USP25 in NSCLC tissues and non-tumor tissues. (B,F) Real-time PCR analysis to quantify the levels of miR-200c, USP25 in NSCLC tissues with lymphatic metastasis (Nx), distant metastasis (T) or without metastasis (N0). (C,G) Real-time PCR analysis to quantify the levels of miR-200c, USP25 in the NSCLC patients with clinical early-stage (1/2AB) or advanced-stage (3/4AB). (D,H) Real-time PCR analysis to quantify the levels of miR-200c, USP25 in the NSCLC patients with tumor size <3 cm or >3 cm. (I) Real-time PCR analysis the levels of USP25 in patients with low and high miR-200c expression levels. Statistical analysis was performed using Student’s t- test. Error bars represent S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001.